$PGEN

Lehr Donald P. sold $127K of PGEN

Lehr Donald P. (Chief Legal Officer) sold 29,131 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Lehr Donald P.
Published Jun 1, 2026, 8:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGEN
Neutral
medium confidence
Mentioned
$PGEN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENNeutralLow
01

Why it matters

The disclosure provides a concrete datapoint on insider behavior (open-market sale by CLO) but lacks any new operational or clinical development that would re-rate the company’s fundamentals.

02

Market read

Traders may monitor for follow-on insider activity or correlate with upcoming corporate catalysts, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No context is given on total insider holdings changes, prior sales cadence, or whether other officers/board members also sold/bought around the same period.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-01; reflects sale executed 2026-05-28.

Background

The article is an SEC Form 4 disclosure of an insider’s transaction in Precigen common stock.

Company-level read

Ticker impact

$PGENNeutralMedium confidence
Context

Pre-arranged 10b5-1 plan was not used; Chief Legal Officer Donald Lehr sold 29,131 shares of Precigen at $4.36 on 2026-05-28.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to sentiment/flow effects around the filing date.

Evidence & confidence

The filing is an SEC Form 4 insider transaction with disclosed sale size and price, but no accompanying corporate event (earnings, trial result, deal, or guidance change) is provided.

Market effects

Limited read-through to biotech/clinical pipeline peers; this is company-specific insider activity without sector-wide catalyst.

None indicated; US-listed microcap/small-cap flow only.

None indicated.

Counterpoint

The sale may be routine liquidity/compensation-related and does not necessarily signal negative fundamentals, especially without evidence of other concurrent insider selling.

Key entities

  • PRECIGEN, INC.

    Subject of the insider transaction disclosure (Form 4).

  • Donald P. Lehr

    Chief Legal Officer who sold shares; transaction reported as open-market sale without a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

$PGENMed

Precigen (PGEN) Q2 2026 Earnings Call Transcript

Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.

$PGENMed

PRECIGEN, INC. (PGEN): Results of Operations and Financial Condition

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro

$PGENMedAI 9/10

Precigen Presents New Long-Term Durability Data for PAPZIMEOS, Recently Granted Seven-Year Market Exclusivity, Demonstrating Complete Responses Beyond 4 Years

Precigen (Nasdaq: PGEN) reported updated long-term durability data for PAPZIMEOS (zopapogene imadenovec-drba) in adults with recurrent respiratory papillomatosis. According to the company, 15 of 18 complete responders (83%) had ongoing complete responses for at least 36 months as of April 30, 2026, with 5 beyond 4 years; median duration not yet reached and no new safety events were observed. The FDA granted seven-year orphan drug market exclusivity.